Malaysia

Population 2015: 30 million

Tuberculosis profile

### Mortality (excludes HIV+TB)
- Rate: 2.4 (1.4–3.8)
- 7.9 (4.5–12)

### Mortality (HIV+TB only)
- Rate: 0.23 (0.059–0.52)
- 0.77 (0.19–1.7)

### Incidence (includes HIV+TB)
- Rate: 27 (23–31)
- 89 (77–103)

### Incidence (HIV+TB only)
- Rate: 1.5 (1.2–1.7)
- 4.8 (4.1–5.6)

### Incidence (MDR/RR-TB)**
- Rate: 0.53 (0.41–0.64)
- 1.7 (1.4–2.1)

### Estimated TB incidence by age and sex (thousands)*, 2015

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>1.5 (0.97–2)</td>
<td>1.3 (0.9–1.7)</td>
<td>2.8 (2.1–3.4)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>8.7 (5.8–12)</td>
<td>16 (12–19)</td>
<td>24 (22–27)</td>
</tr>
<tr>
<td>Total</td>
<td>10 (6.8–14)</td>
<td>17 (13–21)</td>
<td>27 (23–31)</td>
</tr>
</tbody>
</table>

### TB case notifications, 2015
- Total cases notified: 24,220
- Total new and relapse: 23,565
- % tested with rapid diagnostics at time of diagnosis: 2%
- % with known HIV status: 98%
- % pulmonary: 87%
- % bacteriologically confirmed among pulmonary: 75%

### TB treatment coverage (notified/estimated incidence), 2015
- 87% (75–100)

### TB patients facing catastrophic total costs
- 0.1 (0.06–0.15)

### TB/HIV care in new and relapse TB patients, 2015
- Patients with known HIV-status who are HIV-positive: 1,157 (5%)
- on antiretroviral therapy: 574 (50%)

### Drug-resistant TB care, 2015
- New cases: 350 (270–430)
- Previously treated cases: 1.5% (1.2–1.9)
- Total number***: 3.1% (1.3–5.9)
- % notified tested for rifampicin resistance: 44%
- % with known HIV status: 54%
- 16,565
- MDR/RR-TB cases tested for resistance to second-line drugs
- Laboratory-confirmed cases

### Treatment success rate and cohort size
- New and relapse cases registered in 2014: 78% (23,982)
- Previously treated cases, excluding relapse, registered in 2014: 59% (637)
- HIV-positive TB cases, all types, registered in 2014: 52% (1,400)
- MDR/RR-TB cases started on second-line treatment in 2013: 62% (68)
- XDR-TB cases started on second-line treatment in 2013: 0% (1)

### TB preventive treatment, 2015
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 71%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

### TB financing, 2016
- National TB budget (US$ millions): 15
- Funding source: 100% domestic, international, 0% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2017-09-26

Data: www.who.int/tb/data